Clinical trials: fluorouracil
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Claudin 18.2 or CLDN18.2 is a protein found on cells in the digestive system. It is also found in some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors.
- Trial name
- NCT07673887
- Testing
- ASP2138, Pembrolizumab, Oxaliplatin
- Where
- 8 sites in United States, China and 2 more
- Volunteers
- 570 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Gastric Cancer
A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer
This is a Phase 3, multicenter, randomized, double-blind, placebo controlled study of Rilotumumab (AMG 102) with Cisplatin and Capecitabine (CX) for untreated advanced mesenchymal epithelial transition factor (MET)-positive…
- Trial name
- RILOMET-2 (NCT02137343)
- Testing
- Rilotumumab, Cisplatin, Capecitabine
- Where
- 25 sites in Japan, South Korea
- Volunteers
- 34 people
- Sponsor
- Amgen
Head and Neck Squamous Cell Carcinoma
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in participants with head and neck squamous cell…
- Trial name
- ELEVATE HNSCC (NCT04854499)
- Testing
- Magrolimab, Pembrolizumab, Docetaxel
- Where
- 88 sites in United States, Australia and 9 more
- Volunteers
- 193 people
- Sponsor
- Gilead Sciences
Colon Cancer, Rectal Cancer
A Study of Ramucirumab or Icrucumab in Colorectal Cancer
The purpose of this study is to determine if participants with metastatic colorectal cancer live longer without their cancer progressing when treated with standard chemotherapy, standard chemotherapy plus ramucirumab, or standard…
- Trial name
- NCT01111604
- Testing
- Ramucirumab, Icrucumab, mFOLFOX-6
- Where
- 17 sites in United States, Canada
- Volunteers
- 158 people
- Sponsor
- Eli Lilly and Company
Neoplasms, Colorectal
Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
The purpose of this study is to determine the highest, tolerated dose level and safety of lapatinib, capecitabine and oxaliplatin in subjects with advanced cancer and to determine the clinical activity of the combination of drugs…
- Trial name
- NCT00536809
- Testing
- lapatinib, oxaliplatin, capecitabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Rectal Neoplasms
CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision
Primary objective: Pathological complete response (ypT0N0) rate Secondary objectives: Histopathological R0 resection rate Pathological downstaging (ypT0-T2N0) rate One month surgical complication rate Predictive value of…
- Trial name
- NCT00174616
- Testing
- Oxaliplatin, capecitabine, radiotherapy
- Where
- 7 sites in Belgium, France and 5 more
- Volunteers
- 87 people
- Sponsor
- Sanofi
Breast Neoplasms
BIG 02/98 Docetaxel - Breast Cancer
Primary objectives: To compare Disease-Free Survival (DFS) of an adjuvant treatment with docetaxel given either sequentially or in combination with doxorubicin and followed by CMF to doxorubicin alone or in combination with…
- Trial name
- NCT00174655
- Testing
- Doxorubicine + docetaxel sequential, doxorubicine + cyclophosphamide sequential, doxorubicine + cyclophosphamide combined
- Where
- 21 sites in Australia, Austria and 19 more
- Volunteers
- 2,887 people
- Sponsor
- Sanofi
Advanced Solid Tumours
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
This is a phase Ib/II, open-label multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 plus durvalumab alone or in combination with chemotherapy in patients with…
- Trial name
- NCT03421353
- Testing
- AZD9150, Durvalumab, Cisplatin
- Where
- 6 sites in United States
- Volunteers
- 76 people
- Sponsor
- AstraZeneca
Gastrointestinal Cancer, Metastatic
A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
This study is open to adults with advanced colorectal cancer or with advanced pancreatic cancer. The study has 2 parts. In the first part, participants with colorectal cancer get a medicine called BI 905711 combined with…
- Trial name
- NCT05087992
- Testing
- BI 905711, FOLFIRI, Bevacizumab
- Where
- 5 sites in United States, Belgium and 3 more
- Volunteers
- 13 people
- Sponsor
- Boehringer Ingelheim
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
This is a study of pembrolizumab (MK-3475) for advanced gastric or gastroesophageal junction adenocarcinoma; pembrolizumab will be given as monotherapy to participants who have had previous treatment or who are treatment-naïve…
- Trial name
- NCT02335411
- Testing
- pembrolizumab, cisplatin, 5-FU
- Volunteers
- 318 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer, Lung Cancer
Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors
This is a Phase I, multi-center study of GM-CT-01, which has been shown to increase the anti-tumor activity of 5-fluorouracil in mice.
- Conditions
- Colorectal Cancer, Lung Cancer, Breast Cancer, Head and Neck Cancer
- Trial name
- NCT00054977
- Testing
- GM-CT-01, 5-fluorouracil
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Galectin Therapeutics Inc.
Gastrointestinal Cancer
Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer
This is a multicenter, open-label phase Ib/IIa clinical study conducted in China, aimed at evaluating the safety tolerance, efficacy, pharmacokinetic (PK) characteristics, and immunogenicity of DR30206 in combination with…
- Trial name
- NCT07056777
- Testing
- DR30206, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Rectal Cancer
A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer
This study will assess the efficacy and safety of two different neoadjuvant treatment approaches including bevacizumab in newly diagnosed participants with high risk locally advanced rectal cancer.
- Trial name
- INOVA (NCT00865189)
- Testing
- Bevacizumab, Oxaliplatin, Folinic Acid
- Where
- 40 sites in France
- Volunteers
- 91 people
- Sponsor
- Hoffmann-La Roche
Colorectal Carcinoma, Liver Metastases
FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma
This pilot study will evaluate the safety and effectiveness of chemo-radiotherapy comprising a regimen of FOLFOX6 chemotherapy plus SIR-Spheres yttrium-90 microspheres (chemo-radiotherapy, also known as "chemo-SIRT"), in…
- Trial name
- FAST (NCT00735241)
- Testing
- SIR-Spheres microspheres, FOLFOX6 cycles 1-3, FOLFOX6 cycles 4 onwards
- Where
- 3 sites in United States
- Sponsor
- Sirtex Medical
Colorectal Carcinoma
Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma
The purpose of this study is to exploratorily examine efficacy and safety in the participants with chemotherapy-naïve unresectable, advanced/recurrent colorectal carcinoma of Kirsten rat sarcoma-2 virus (KRAS) wild-type who have…
- Trial name
- SAPPHIRE (NCT02337946)
- Testing
- oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
- Where
- 49 sites in Japan
- Volunteers
- 164 people
- Sponsor
- Takeda
Colorectal Cancer
Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer
The purpose of this study is to determine if panitumumab, in combination with irinotecan, leucovorin, and 5-fluorouracil (5-FU) is safe and efficacious in patients with metastatic colorectal cancer.
- Trial name
- NCT00111761
- Testing
- Irinotecan, Panitumumab, 5-Fluorouracil
- Volunteers
- 43 people
- Sponsor
- Amgen
Uterine Neoplasms
Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer
Primary: To assess the overall response rate of oxaliplatin in patients with bidimensionally measurable disease at baseline. Secondary: To assess the safety and tolerability of oxaliplatin To assess time to progression and…
- Trial name
- NCT00782041
- Testing
- Oxaliplatin, 5-FluoroUracil, Folinic acid
- Where
- Thailand
- Volunteers
- 11 people
- Sponsor
- Sanofi
Cancer
Lapatinib in Combination With Vinorelbine
This is a randomized, parallel-arm, open-label, multi-centre, Phase II study to determine the efficacy and safety of lapatinib in combination with vinorelbine or capecitabine in women with ErbB2 overexpressing metastatic breast…
- Trial name
- VITAL (NCT01013740)
- Testing
- Vinorelbine, Lapatinib, Capecitabine
- Where
- 53 sites in Bulgaria, Chile and 8 more
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer Metastatic
Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer
Primary Objective: Efficacy: To assess the progression-free survival rate at 10 months in patients on maintenance therapy with capecitabine plus aflibercept.
- Trial name
- Drop and Go (NCT02085005)
- Testing
- Capecitabine, Aflibercept AVE0005, Oxaliplatin SR96669
- Sponsor
- Sanofi
HER2+ Metastatic Breast Cancer (MBC)
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
This is a randomized, multi-center, multinational, open-label, active-controlled, parallel design study of the combination of neratinib plus capecitabine versus the combination of lapatinib plus capecitabine in HER2+ MBC patients…
- Trial name
- NALA (NCT01808573)
- Testing
- neratinib, capecitabine, lapatinib
- Where
- 252 sites in United States, Argentina and 26 more
- Volunteers
- 621 people
- Sponsor
- Puma Biotechnology, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.